Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: a proof of concept.
Humans
Female
Male
Middle Aged
Disease Progression
Pancreatic Neoplasms
/ diagnostic imaging
Aged
Stomach Neoplasms
/ diagnostic imaging
Tomography, X-Ray Computed
/ methods
Adult
ROC Curve
Neuroendocrine Tumors
/ diagnostic imaging
Intestinal Neoplasms
/ diagnostic imaging
Proof of Concept Study
Tumor Burden
Disease progression
GEP-NETs
RECISTv1.1
RLT
TGR
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 Jul 2024
09 Jul 2024
Historique:
received:
04
01
2024
accepted:
03
07
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
9
7
2024
Statut:
epublish
Résumé
This study aims to assess the predictive capability of cylindrical Tumor Growth Rate (cTGR) in the prediction of early progression of well-differentiated gastro-entero-pancreatic tumours after Radio Ligand Therapy (RLT), compared to the conventional TGR. Fifty-eight patients were included and three CT scans per patient were collected at baseline, during RLT, and follow-up. RLT response, evaluated at follow-up according to RECIST 1.1, was calculated as a percentage variation of lesion diameters over time (continuous values) and as four different RECIST classes. TGR between baseline and interim CT was computed using both conventional (approximating lesion volume to a sphere) and cylindrical (called cTGR, approximating lesion volume to an elliptical cylinder) formulations. Receiver Operating Characteristic (ROC) curves were employed for Progressive Disease class prediction, revealing that cTGR outperformed conventional TGR (area under the ROC equal to 1.00 and 0.92, respectively). Multivariate analysis confirmed the superiority of cTGR in predicting continuous RLT response, with a higher coefficient for cTGR (1.56) compared to the conventional one (1.45). This study serves as a proof of concept, paving the way for future clinical trials to incorporate cTGR as a valuable tool for assessing RLT response.
Identifiants
pubmed: 38982134
doi: 10.1038/s41598-024-66668-9
pii: 10.1038/s41598-024-66668-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15782Informations de copyright
© 2024. The Author(s).
Références
Das, S. & Dasari, A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: Are there global differences?. Curr. Oncol. Rep. 23(4), 43. https://doi.org/10.1007/s11912-021-01029-7 (2021).
doi: 10.1007/s11912-021-01029-7
pubmed: 33719003
pmcid: 8118193
Dasari, A. et al. Trends in the Incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3(10), 1335. https://doi.org/10.1001/jamaoncol.2017.0589 (2017).
doi: 10.1001/jamaoncol.2017.0589
pubmed: 28448665
pmcid: 5824320
Leoncini, E. et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 58(2), 368–379. https://doi.org/10.1007/s12020-017-1273-x (2017).
doi: 10.1007/s12020-017-1273-x
pubmed: 28303513
pmcid: 5671554
White, B. E. et al. Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study. Lancet Reg. Health–Europe. 23, 100510. https://doi.org/10.1016/j.lanepe.2022.100510 (2022).
doi: 10.1016/j.lanepe.2022.100510
WHO, IARC, eds. Digestive System Tumours. 5th ed. International agency for research on cancer; 2019.
Rindi, G. et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr. Pathol. 33(1), 115–154. https://doi.org/10.1007/s12022-022-09708-2 (2022).
doi: 10.1007/s12022-022-09708-2
pubmed: 35294740
Cives, M. & Strosberg, J. R. Gastroenteropancreatic neuroendocrine tumors. CA A Cancer J. Clin. 68(6), 471–487. https://doi.org/10.3322/caac.21493 (2018).
doi: 10.3322/caac.21493
Pavel, M. et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(7), 844–860. https://doi.org/10.1016/j.annonc.2020.03.304 (2020).
doi: 10.1016/j.annonc.2020.03.304
pubmed: 32272208
AGENZIA ITALIANA DEL FARMACO | DETERMINA 11 marzo 2019. https://www.aifa.gov.it/documents/20142/847786/Determina_501-2019_Lutathera.pdf
Lutathera | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera
Strosberg, J. et al. Phase 3 trial of
doi: 10.1056/NEJMoa1607427
pubmed: 28076709
pmcid: 5895095
Strosberg, J. R. et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22(12), 1752–1763. https://doi.org/10.1016/S1470-2045(21)00572-6 (2021).
doi: 10.1016/S1470-2045(21)00572-6
pubmed: 34793718
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 11). Eur. J. Cancer 45(2), 228–247. https://doi.org/10.1016/j.ejca.2008.10.026 (2009).
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI: J. Natl. Cancer Inst. 92(3), 205–216. https://doi.org/10.1093/jnci/92.3.205 (2000).
doi: 10.1093/jnci/92.3.205
pubmed: 10655437
Sundin, A. & Rockall, A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: The challenges ahead. Neuroendocrinology 96(4), 261–271. https://doi.org/10.1159/000342270 (2012).
doi: 10.1159/000342270
pubmed: 22907438
Van Essen, M., Sundin, A., Krenning, E. P. & Kwekkeboom, D. J. Neuroendocrine tumours: The role of imaging for diagnosis and therapy. Nat. Rev. Endocrinol. 10(2), 102–114. https://doi.org/10.1038/nrendo.2013.246 (2014).
doi: 10.1038/nrendo.2013.246
pubmed: 24322649
Das, S., Al-Toubah, T., El-Haddad, G. & Strosberg, J.
doi: 10.1080/17474124.2019.1685381
pubmed: 31652074
pmcid: 7227421
Hicks, R. J. et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology 105(3), 295–309. https://doi.org/10.1159/000475526 (2017).
doi: 10.1159/000475526
pubmed: 28402980
Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr 3 ] octreotate: Toxicity, efficacy, and survival. JCO 26(13), 2124–2130. https://doi.org/10.1200/JCO.2007.15.2553 (2008).
doi: 10.1200/JCO.2007.15.2553
Choi, U. S., Kawaguchi, H., Matsuoka, Y., Kober, T. & Kida, I. Brain tissue segmentation based on MP2RAGE multi-contrast images in 7 T MRI. PLoS One https://doi.org/10.1371/journal.pone.0210803 (2019).
doi: 10.1371/journal.pone.0210803
pubmed: 31887181
pmcid: 6936865
Huizing, D. M. V. et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging 20(1), 57. https://doi.org/10.1186/s40644-020-00335-w (2020).
doi: 10.1186/s40644-020-00335-w
pubmed: 32778165
pmcid: 7418334
Luo, Y. et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?. BMC Cancer 17(1), 154. https://doi.org/10.1186/s12885-017-3150-7 (2017).
doi: 10.1186/s12885-017-3150-7
pubmed: 28231773
pmcid: 5324282
Solis-Hernandez, M. P. et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br. J. Cancer 121(7), 537–544. https://doi.org/10.1038/s41416-019-0558-7 (2019).
doi: 10.1038/s41416-019-0558-7
pubmed: 31477779
pmcid: 6889276
Van Treijen, M. J. C. et al. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST?. Abdom. Radiol. 47(3), 1071–1081. https://doi.org/10.1007/s00261-021-03393-1 (2022).
doi: 10.1007/s00261-021-03393-1
Rodallec, M. et al. Endocrine pancreatic tumours and helical CT: Contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6(1–2), 77–85. https://doi.org/10.1159/000090026 (2006).
doi: 10.1159/000090026
pubmed: 16327283
Ferté, C. et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin. Cancer Res. 20(1), 246–252. https://doi.org/10.1158/1078-0432.CCR-13-2098 (2014).
doi: 10.1158/1078-0432.CCR-13-2098
pubmed: 24240109
Smith, A. D., Shah, S. N., Rini, B. I., Lieber, M. L. & Remer, E. M. Morphology, attenuation, size, and structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. Am. J. Roentgenol. 194(6), 1470–1478. https://doi.org/10.2214/AJR.09.3456 (2010).
doi: 10.2214/AJR.09.3456
Stein, W. D. et al. Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin. Cancer Res. 18(8), 2374–2381. https://doi.org/10.1158/1078-0432.CCR-11-2275 (2012).
doi: 10.1158/1078-0432.CCR-11-2275
pubmed: 22344231
pmcid: 3328595
De Mestier, L. et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: State of the art. Endocr.-Relat. Cancer 21(3), R105–R120. https://doi.org/10.1530/ERC-13-0365 (2014).
doi: 10.1530/ERC-13-0365
pubmed: 24351682
Dromain, C. et al. Tumor growth rate to predict the outcome of patients with neuroendocrine tumors: Performance and sources of variability. Neuroendocrinology 111(9), 831–839. https://doi.org/10.1159/000510445 (2021).
doi: 10.1159/000510445
pubmed: 32717738
Lamarca, A. et al. Value of tumor growth rate (TGR) as an early biomarker predictor of patients’ outcome in neuroendocrine tumors (NET)—the GREPONET study. Oncologist. 24(11), e1082–e1090. https://doi.org/10.1634/theoncologist.2018-0672 (2019).
doi: 10.1634/theoncologist.2018-0672
pubmed: 30910869
pmcid: 6853102
Lamarca, A. et al. Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: The GREPONET-2 study. Clin. Cancer Res. 25(22), 6692–6699. https://doi.org/10.1158/1078-0432.CCR-19-0963 (2019).
doi: 10.1158/1078-0432.CCR-19-0963
pubmed: 31375514
Dromain, C. et al. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer 19(1), 66. https://doi.org/10.1186/s12885-018-5257-x (2019).
doi: 10.1186/s12885-018-5257-x
pubmed: 30642293
pmcid: 6332566
Pettersson, O. J., Fröss-Baron, K., Crona, J. & Sundin, A. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE. Endocr. Connect. 10(4), 422–431. https://doi.org/10.1530/EC-21-0027 (2021).
doi: 10.1530/EC-21-0027
pubmed: 33875614
pmcid: 8111309
Wang, S. J. et al. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. J. Neuroendocrinol. 35(4), e13260. https://doi.org/10.1111/jne.13260 (2023).
doi: 10.1111/jne.13260
pubmed: 37002881
Collins, V. P. Observations on growth rates of human tumors. AJR. 76, 988–1000 (1956).
Wadell, H. Volume, shape, and roundness of rock particles. J. Geol. 40(5), 443–451. https://doi.org/10.1086/623964 (1932).
doi: 10.1086/623964
Akaike, H. Information theory and an extension of the maximum likelihood principle. In: Selected Papers of Hirotugu Akaike. Springer; 1998:199–213.
Schwarz, G. Estimating the dimension of a model. Ann. Statist. https://doi.org/10.1214/aos/1176344136 (1978).
doi: 10.1214/aos/1176344136
Youden, W. J. Index for rating diagnostic tests. Cancer 3(1), 32–35. https://doi.org/10.1002/1097-0142(1950)3:1%3c32::AID-CNCR2820030106%3e3.0.CO;2-3 (1950).
doi: 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
pubmed: 15405679
Prasad, V. et al. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: A need for standardised practice. Eur. J. Nucl. Med. Mol. Imaging 47(10), 2358–2371. https://doi.org/10.1007/s00259-020-04712-2 (2020).
doi: 10.1007/s00259-020-04712-2
pubmed: 32062681
pmcid: 7396404
Caplin, M. E. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Eng. J. Med. 371(3), 224–233 (2014).
doi: 10.1056/NEJMoa1316158